Xtant Medical entered into a securities purchase agreement to sell Xtant common stock and warrants to a group of accredited investors led. Gross proceeds are expected to be approximately $9.75 million, before deducting offering expenses.
Net proceeds will support working capital and other general corporate purposes.
Xtant Medical focuses on the design, development and commercialization of a portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.
Xtant Medical entered into a securities purchase agreement to sell Xtant common stock and warrants to a group of accredited investors led. Gross proceeds are expected to be approximately $9.75 million, before deducting offering expenses.
Net proceeds will support working capital and other general corporate purposes.
Xtant Medical focuses on...
Xtant Medical entered into a securities purchase agreement to sell Xtant common stock and warrants to a group of accredited investors led. Gross proceeds are expected to be approximately $9.75 million, before deducting offering expenses.
Net proceeds will support working capital and other general corporate purposes.
Xtant Medical focuses on the design, development and commercialization of a portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures.
Copy to clipboard 
